CA-NOMINAL
22.4.2024 19:29:30 CEST | Business Wire | Press release
Nominal, a company specializing in creating end-to-end data analysis solutions for industrial engineering teams, emerged from stealth to provide a faster, more reliable way to review test data and validate mission-critical systems. The startup raised $7.5M in Seed funding led by Lux Capital with support from Founders Fund and $20M in their Series A led by General Catalyst. Additional investors include Haystack VC, XYZ Ventures, Human Capital, Box Group, and Overmatch.
Nominal specializes in creating software solutions for the Aerospace, Defense, Industrial Machinery, Transportation, and Energy sectors with various partnerships across the U.S. government. The company is led by co-founder and CEO Cameron McCord, who has extensive experience in the private sector at prominent startups Anduril, Applied Intuition, and Saildrone and as a venture capitalist, and in the public sector as a veteran Nuclear Submarine Officer and Congressional Liaison for the Navy. McCord works closely with his co-founders Bryce Strauss, a former Lockheed Martin Space division systems engineer who worked on inter-planetary robotic missions and building software tools for engineers, and Jason Hoch, an experienced software engineer who has diverse experience creating data products for startups, Fortune 500 companies, and governments.
Nominal's platform is designed to handle sensitive government and industrial data. The company's leadership team brings over 15 years of combined experience in both hardware and software from organizations like SpaceX, Palantir, Anduril, Applied Intuition, NASA, Microsoft, and more.
“Building trust in industrial systems and the data that these systems generate is core to our mission at Nominal. As aerospace, defense, and industrial systems have rapidly become more complex and software-defined, the software tools and infrastructure that engineers and operators use to make sense of and validate these systems have lagged in a costly and dangerous way.” Cameron McCord, Co-founder and CEO of Nominal said, “We’re choosing now to come out of stealth because we feel ready to accelerate our mission to help engineers that develop, test, and validate mission-critical industrial systems. We are on an industrial software collision course. Time is ticking - for our commercial customers, this means getting a product safely to market faster, and for our government customers, it means fielding reliable and tested systems for any mission.”
With Nominal, teams can quickly test and deploy their complex hardware systems. Nominal is dedicated to providing a robust, end-to-end solution that simplifies workflows, fosters collaboration, and seamlessly scales with the evolving needs of its valued customers and partners. Nominal also enables teams and organizational-level collaboration and visibility to reflect the multidisciplinary and iterative nature of engineering. The more people in an engineering organization who can view a comprehensive data story, the better the understanding and insights gained.
"When we first met Nominal, what stood out to us was the intentionality by which Cameron, Bryce, and Jason are building the company. Nominal’s modern software suite is purpose-built for hardware engineers to manage the complex workflows of testing and developing high-stakes, breakthrough hardware systems. By hitting the industrial software collision course head-on, we believe Nominal can help unlock a renaissance of industrial innovation,” said Paul Kwan, Managing Partner, General Catalyst.
Nominal is utilizing this latest infusion of capital to uphold its commitment to delivering innovative solutions to the defense and aerospace sectors, including the rollout of its full-stack data analysis solution designed to facilitate and expedite the process of analyzing and reviewing test data for engineering teams. Beyond new product initiatives to meet growing customer demands, the company also intends to grow its teams and enhance its security and deployment capabilities.
About Nominal
Nominal is igniting the next industrial revolution. By allowing for rapid and accurate review of test data and the validation of critical systems through its comprehensive data analysis platform, Nominal provides modern workflows specifically tailored to the needs of engineering teams that develop, validate, and monitor hardware. At Nominal, we believe hardware engineers deserve the world’s best software. We are fully committed to helping our users more efficiently and effectively test and deploy mission-critical systems that will change the world. Nominal currently supports mission-critical data analysis and testing at companies across the aerospace, defense, energy, and industrial spheres including Varda Space, Muon Space, REGENT, Radiant Nuclear, the U.S. Air Force, and others. We are supported by leading venture investors such as General Catalyst, Lux Capital, Founders Fund, Haystack, XYZ Ventures, Human Capital, BoxGroup, and Overmatch. To learn more about Nominal and its innovative solutions, please visit nominal.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418799842/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
